Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LEGN
LEGEND BIOTECH CORPORATION
NASDAQ
$19.88
▼ DOWN 3.02% (-0.62)

KEY STATISTICS

Market Cap$3.68 B
52w High$37.50
52w Low$16.24
Dividend Yield—
Frequency—
P/E-29.24
Volume1.15M
Shares Out.184.94M

COMPANY

LEADERSHIP

Alan S. Bash
CHIEF EXECUTIVE
Alan S. Bash

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 5, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
3,200

PRICE TARGET

Target High$78.00
Target Low$28.00
Target Median$59.00
Target Consensus$57.22

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$361.43M
NOV
11
WED

PRICE

$19.88 ▼ DOWN 3.02% (−$0.62)
$20.00$20.20$20.409:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM19.88

About Legend Biotech Corporation

https://www.legendbiotech.com ↗

Legend Biotech, a clinical-stage biopharma, develops novel cell therapies for oncology and other indications, with lead candidate LCAR-B38M for multiple myeloma and a portfolio of CAR-T and autologous therapies in clinical trials globally.

INDUSTRY

Biotechnology

A PRODUCT LEGEND BIOTECH CORPORATION IS KNOWN FOR

Carvykti (ciltacabtagene autoleucel)
Carvykti (ciltacabtagene autoleucel)

Carvykti is a FDA-approved, personalized BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma, representing a novel, one-time treatment and a key revenue driver for Legend Biotech.

COMPETITORS

COMPETITOR
BMY COMPARE
GILD COMPARE
NVS COMPARE

Revenue by Products

IconPRODUCTFY2020FY2021
Licensing Of Intellectual Property$5.63M $4.91M ▼

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
UNITED STATES— $234.73M $434.71M ▲$746.1M ▲
Europe— $15.07M $47.87M ▲—
CHINA$328K $179K ▼$320K ▲$26.6M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
193
LISTED HERE
26
RANKED BY POSITION SIZE
IBB
0.22% · 1.1M
PBE
1.57% · 311.7K
CANC
1.86% · 197.9K
GNOM
2.26% · 105.3K
FBCG
0.03% · 94.0K
SPEM
0.01% · 91.5K
XEMD.L
0.01% · 87.4K
AEMD.L
0.02% · 82.4K
UB30.L
0.01% · 74.3K
H4ZP.DE
0.12% · 63.7K
KURE
0.78% · 43.9K
MEDI
1.99% · 42.4K
BBP
0.70% · 40.8K
CN
CNCR
3.20% · 38.0K
EMSF
1.60% · 36.0K
CXSE
0.13% · 30.6K
AVEM
0.00% · 23.0K
WELP.L
2.34% · 17.6K
GEM
0.02% · 15.3K
ZEM.TO
0.00% · 5.1K
GERD.L
0.00% · 3.1K
BIB
0.06% · 3.0K
APIE
0.00% · 1.8K
JDOC
0.33% · 1.5K
ESIM
0.07% · 655
PABE.L
0.05% · 208

INSTITUTIONAL OWNERSHIP

SHARES OWNED
44.77%
HOLDERS
311
TOP 12 OF 311 · RANKED BY POSITION SIZE
Fmr LLC
29.1M sh · $840.23M
Deerfield Management Company, L.P. (Series C)
8.1M sh · $235.01M
Suvretta Capital Management, LLC
7.6M sh · $137.14M
Westfield Capital Management Co LP
6.2M sh · $134.02M
Hhlr Advisors, Ltd.
6.0M sh · $172.83M
Blackrock Inc.
5.7M sh · $253.4M
Blackrock, Inc.
4.7M sh · $136.5M
Point72 Asset Management, L.P.
3.9M sh · $70.3M
Goldman Sachs Group Inc
3.7M sh · $105.77M
Kynam Capital Management, LP
3.0M sh · $86.67M
Artisan Partners Limited Partnership
2.5M sh · $83.09M
First Beijing Investment Ltd
2.3M sh · $41.54M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
OFFICER: INTERIM CEO
BASH ALAN
Purchase · 4.9K shares
2026-08-14
★
OFFICER: INTERIM CEO
BASH ALAN
— · —
2026-07-24
★
DIRECTOR
Casey Patrick John
Sale · 6.0K shares
2026-06-30
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Huang Ying
Sale · 3.4K shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 4
PERFORM 1
OUTPERFORM 1
HOLD 1
BUY 1
NEUTRAL 1
9 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Morgan Stanley OVERWEIGHT Oppenheimer PERFORM RBC Capital OUTPERFORM TD Cowen HOLD HC Wainwright & Co. BUY UBS NEUTRAL Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
SRRK$57.80COMPARE
CGON$74.34COMPARE
XENE$59.99COMPARE
CELC$88.44COMPARE
ADPT$25.19COMPARE
IDYA$40.11COMPARE
TARS$71.76COMPARE
IRON$80.03COMPARE